Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Dapagliflozin, Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 20
States / cities: Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more

Conditions: Myelodysplastic Syndrome
Interventions: Oral Azacitidine, Placebo, Best Supportiv Care (BSC); Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Duarte, California + 31 more

Conditions: Rhinitis, Allergic, Perennial
Interventions: FPNS, FFNS, placebo FFNS, placebo FPNS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more

Conditions: Alzheimers Disease
Interventions: CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 78
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more

Conditions: Hidradenitis Suppurativa
Interventions: AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 36
States / cities: Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more

Conditions: Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Interventions: Sonlicromanol, Placebo; Drug
Lead sponsor: Khondrion BV; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Cleveland, Ohio • Houston, Texas

Conditions: Herpes Labialis
Interventions: Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 570, AMG 570 Matching Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin

Conditions: Chronic Kidney Diseases
Interventions: COR-001, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Lupus Nephritis (LN)
Interventions: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Smoking Cessation
Interventions: Cytisine, Placebo Comparator, Behavioral support; Drug · Behavioral
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Tempe, Arizona • Burbank, California • Lexington, Kentucky + 5 more

Conditions: Parkinson's Disease
Interventions: perampanel, placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: New Haven, Connecticut • The Woodlands, Texas

Conditions: Alzheimer Disease
Interventions: PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 12
States / cities: Sun City, Arizona • Fresno, California • San Diego, California + 9 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 44 more

Conditions: Hearing Loss, Cochlear Trauma
Interventions: Ebselen, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more

Conditions: Constipation
Interventions: Prucalopride, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more

Conditions: Healthy Volunteers
Interventions: TAK-020, TAK-020 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia
Interventions: Placebo, Lu AF11167; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Asthma
Interventions: Fluticasone propionate, Placebo, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: Doxazosin, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Schizophrenia
Interventions: CAD-9303, Placebos; Drug
Lead sponsor: Cadent Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more

Search by objective public record fields.

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

Single Ascending Dose Study of AMG 570 in Healthy Subjects

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Dapagliflozin in Active Lupus Nephritis

Trial of Cytisine in Adult Smokers

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

SPI-1005 in Adults Receiving Cochlear Implant

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Study of CAD-9303 in Subjects With Schizophrenia

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia